Table 6– Pooled treatment outcomes by extensively drug-resistant tuberculosis (XDR-TB) patient group
XDR aloneXDR+2sliXDR+sliG4#XDR+sliG4EZ
Treatment success43 (27–58)30 (17–43)3419 (0–48)
Treatment failure20 (15–25)29 (8–50)3326 (14–38)
Death13 (6–20)18 (7–29)30 (18–41)35 (21–50)
Treatment failure or death35 (26–45)54 (40–69)4849 (37–61)
Defaulted15 (5–24)15 (3–27)1819 (6–32)
  • Data are presented as % (95% CI) or %. XDR alone: resistance to isoniazid and rifampicin, plus any fluoroquinolone and any second-line injectable drug (sli); XDR+2sli: XDR-TB, plus resistance to both an aminoglycoside injectable (kanamycin/amikacin) and to capreomycin; XDR+sliG4: XDR-TB, plus resistance to all second-line TB drugs tested, with, as a minimum, resistance to kanamycin and to at least one group 4 (G4) drug; XDR+sliG4EZ: XDR-TB, plus resistance to all first- and second-line TB drugs tested, with, as a minimum, resistance to kanamycin, one group 4 drug and either pyrazinamide (Z) and/or ethambutol (E). #: pooled estimates were unstable and 95% confidence intervals could not be calculated for some outcomes; : numbers do not always total 100% due to rounding and meta-analytic pooling methods.